May 13 (Reuters) - Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
131 USD | +0.39% | +4.16% | +19.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.94% | 331B | |
+44.70% | 754B | |
+40.87% | 630B | |
-6.28% | 352B | |
+8.59% | 298B | |
+18.60% | 250B | |
+11.89% | 217B | |
-0.74% | 216B | |
+6.35% | 164B | |
+0.10% | 163B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck stops skin cancer combination therapy testing in late-stage study